Loading company…
YMKM Biopharm develops poxvirus-based immunotherapies for malignant solid tumors.
Founded in 2019 and based in Shenzhen, China, YMKM Biopharm develops tumor immunotherapies, particularly oncolytic viruses using poxvirus technology. Its KM1 product was approved for clinical trials in China and the US in September and December 2022, respectively. The company is part of Johnson & Johnson’s Shanghai incubator Jlabs and completed a strategic investment in June 2023.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in